DELRAY BEACH, Fla., Jan. 3, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCBB:PSID), a developer of medical technologies for diabetes management and molecular diagnostic systems, announced today it has partnered with two leading diabetes research organizations, the Diabetes Research Institute (“DRI”) at the University of Miami and Schneider Children’s Medical Center of Israel (“Schneider Children’s”), to support the continued development and study of PositiveID’s diabetes management products.
